A compound of Formula (I) their polymorphs, stereoisomers, solvates, and pharmaceutically acceptable salts thereof, wherein X is selected from O or S; Z is N; A is CR 1 ; B is CR 2 ; D is CR 3 ; R 1 , R 2 , and R 3 are independently selected from hydrogen, or C 1-2 alkyl; R 4 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, C 3-5 cycloalkyl, or C 5-6 aryl, wherein C 1-4 alkyl, and C 1-4 alkoxy, is optionally substituted with one or more of the groups selected from C 1-4 alkyl, and C 1-4 alkoxy; R 11 and R 12 are taken together to form a 5-10 membered monocyclic or bicyclic saturated heterocyclic ring with 1-5 heteroatoms selected from N, S or O, wherein the 5-10 membered monocyclic or bicyclic saturated heterocyclic ring is optionally substituted with the substituents selected from amino, C 1-2 alkylamino, or - NH(CO)CH=CH-CH 2 -N(CH 3 ) 2 ; and R 13 is selected from 5-9 membered monocyclic or bicyclic aryl, and 5-9 membered monocyclic or bicyclic heteroaryl with 1-5 heteroatoms selected from N, S or O, wherein 5-9 membered monocyclic or bicyclic aryl, and 5-9 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1-5 substituents selected from hydroxyl, cyano, fluoro, bromo, chloro, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 3-5 cycloalkyl, C 5-9 aryl, C 1-9 heterocyclyl, or C 1-9 heteroaryl, wherein C 1-4 alkyl, C 1-4 alkoxy, C 3-5 cycloalkyl, C 5-9 aryl, C 1-9 heterocyclyl, and C 1-9 heteroaryl, is optionally substituted with one or more of the groups selected from hydrogen, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 3-5 cycloalkyl, C 5-6 aryl, C 1-6 heteroaryl, C 1-6 heterocyclyl, oxo, halogen, and cyano, wherein C 5-6 aryl, C 1-6 heteroaryl, and C 1-6 heterocyclyl, is optionally substituted with one or more of the groups selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, oxo, halogen, hydroxyl, - CH 2 OH, and cyano. X is selected from O or S; Z is N; A is CR 1 ; B is CR 2 ; D is CR 3 ; R 1 , R 2 , and R 3 are independently selected from hydrogen, or C 1-2 alkyl; R 4 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, C 3-5 cycloalkyl, or C 5-6 aryl, wherein C 1-4 alkyl, and C 1-4 alkoxy, is optionally substituted with one or more of the groups selected from C 1-4 alkyl, and C 1-4 alkoxy; R 11 and R 12 are taken together to form a 5-10 membered monocyclic or bicyclic saturated heterocyclic ring with 1-5 heteroatoms selected from N, S or O, wherein the 5-10 membered monocyclic or bicyclic saturated heterocyclic ring is optionally substituted with the substituents selected from amino, C 1-2 alkylamino, or - NH(CO)CH=CH-CH 2 -N(CH 3 ) 2 ; and R 13 is selected from 5-9 membered monocyclic or bicyclic aryl, and 5-9 membered monocyclic or bicyclic heteroaryl with 1-5 heteroatoms selected from N, S or O, wherein 5-9 membered monocyclic or bicyclic aryl, and 5-9 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1-5 substituents selected from hydroxyl, cyano, fluoro, bromo, chloro, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 3-5 cycloalkyl, C 5-9 aryl, C 1-9 heterocyclyl, or C 1-9 heteroaryl, wherein C 1-4 alkyl, C 1-4 alkoxy, C 3-5 cycloalkyl, C 5-9 aryl, C 1-9 heterocyclyl, and C 1-9 heteroaryl, is optionally substituted with one or more of the groups selected from hydrogen, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 3-5 cycloalkyl, C 5-6 aryl, C 1-6 heteroaryl, C 1-6 heterocyclyl, oxo, halogen, and cyano, wherein C 5-6 aryl, C 1-6 heteroaryl, and C 1-6 heterocyclyl, is optionally substituted with one or more of the groups selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, oxo, halogen, hydroxyl, - CH 2 OH, and cyano. <EOS>